DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Efficacy and Safety Study of Elagolix in Women With Endometriosis

Phase 2

Completed

Conditions: Endometriosis, Pain

Interventions: Drug: Placebo
Drug: Elagolix

First Posted Date: 2009-09-09

Last Posted Date: 2018-09-26

Lead Sponsor: AbbVie

Target Recruit Count: 137

Registration Number: NCT00973973

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: ABT-126
Drug: donepezil

First Posted Date: 2009-07-29

Last Posted Date: 2013-01-31

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 274

Registration Number: NCT00948909

Locations: 🇧🇬
Site Reference ID/Investigator# 22946, Sofia, Bulgaria
🇿🇦
Site Reference ID/Investigator# 20263, Richards Bay, South Africa
🇬🇧
Site Reference ID/Investigator# 20183, Bradford, United Kingdom

and more 26 locations

Study of Adalimumab in Patients With Axial Spondyloarthritis

Phase 3

Completed

Conditions: Axial Spondyloarthritis

Interventions: Biological: Placebo
Biological: Open-label Adalimumab
Biological: Adalimumab

First Posted Date: 2009-07-14

Last Posted Date: 2014-09-09

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 192

Registration Number: NCT00939003

Locations: 🇳🇱
Site Reference ID/Investigator# 21284, Leiden, Netherlands
🇺🇸
Site Reference ID/Investigator# 21246, Wheaton, Maryland, United States
🇺🇸
Site Reference ID/Investigator# 21250, Birmingham, Alabama, United States

and more 35 locations

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction

Phase 2

Completed

Conditions: Pain

Interventions: Drug: ABT-712 Extended-release
Drug: Hydrocodone/Acetaminophen Immediate-release
Drug: Placebo

First Posted Date: 2009-07-09

Last Posted Date: 2014-04-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 122

Registration Number: NCT00935311

Locations: 🇺🇸
Site Reference ID/Investigator# 20744, Salt Lake City, Utah, United States
🇺🇸
Site Reference ID/Investigator# 20743, San Marcos, Texas, United States
🇺🇸
Site Reference ID/Investigator# 20745, Austin, Texas, United States

A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

Phase 2

Completed

Conditions: Diabetic Nephropathy
Chronic Kidney Disease

Interventions: Drug: 0.25 mg Atrasentan QD
Drug: 0.75 mg Atrasentan QD
Drug: 1.75 mg Atrasentan QD
Drug: Placebo for Atrasentan 0.2 mg/mL solution

First Posted Date: 2009-06-15

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 92

Registration Number: NCT00920764

Locations: 🇺🇸
Site Reference ID/Investigator# 16567, Hudson, Florida, United States
🇺🇸
Site Reference ID/Investigator# 21061, Whittier, California, United States
🇺🇸
Site Reference ID/Investigator# 16572, Yuba City, California, United States

and more 25 locations

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: ABT-263
Drug: paclitaxel

First Posted Date: 2009-05-01

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 19

Registration Number: NCT00891605

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: ABT-288
Drug: Placebo

First Posted Date: 2009-04-28

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 81

Registration Number: NCT00888693

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: ABT-263
Drug: gemcitabine

First Posted Date: 2009-04-24

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT00887757

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: ABT-263
Drug: etoposide/cisplatin

First Posted Date: 2009-04-09

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 12

Registration Number: NCT00878449

Locations: 🇺🇸
Site Reference ID/Investigator# 12303, Baltimore, Maryland, United States
🇺🇸
Site Reference ID/Investigator# 13322, New Brunswick, New Jersey, United States
🇺🇸
Site Reference ID/Investigator# 43505, Detroit, Michigan, United States

and more 4 locations

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: ABT-072

First Posted Date: 2009-03-31

Last Posted Date: 2013-04-01

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 5

Registration Number: NCT00872196

Locations: 🇺🇸
Site Reference ID/Investigator# 18222, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy